Stockreport

ROCKLATAN/ROCLANDA Strengthens Market Position with Robust Sales and Patient Outcomes | DelveInsight [Yahoo! Finance]

Ocular Therapeutix, Inc.  (OCUL) 
Last ocular therapeutix, inc. earnings: 3/12 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ocutx.com
PDF This fixed-dose combination merges the benefits of a Rho kinase inhibitor and a prostaglandin F2a analog, providing superior efficacy compared to monotherapies. LAS VE [Read more]